Gynecological Endocrinology · 2018 · 27 citations · 10 references
MedicineGynecologyPharmacotherapyPain ManagementPain MedicineWomen's Health PharmacotherapySymptom CharacterizationVestibular PhysiologyVestibular TestingVulvovaginal DisordersAfferent Nerve FibersFibersHormone Adverse EffectsSystemic Adverse EffectsVestibular InnervationVulvar ErythemaVulvar Vestibulodynia
The study aimed to assess the effects of ospemifene on vulvar vestibule in postmenopausal women with vulvar pain and dyspareunia. Fifty-five postmenopausal women used oral ospemifene 60 mg/d for 60 d. Symptoms of dryness, burning, and dyspareunia were evaluated on a 10 cm visual analog scale. Visual examination of the vulvar vestibule was also conducted. Patients also underwent current perception threshold (CPT) testing obtained from the vulvar vestibule. Fifty-five patients (94.6%) completed the treatment. Hot flashes were the most frequent adverse effects, but this led to a discontinuation of therapy in three patients (5.4%). After therapy, there was a statistically significant decrease from the baseline in the mean scores for dryness, burning, and dyspareunia and reduction of vestibular trophic score (baseline value of 11.2-4.2 after the therapy, p ≤ 002) and cotton swab test scores (2.81 compared with 1.25, p = .001). There was a difference in CPT values for all nerve fibers and more consistent for C fibers (-38% of sensitivity). These results confirm the efficacy of ospemifene on postmenopausal vestibular symptoms and signs; moreover, the drug was effective in normalizing vestibular innervation sensitivity.
10
Kristen B. Levine, Rachel E. Williams, Katherine E. Hartmann · Menopause The Journal of The North American Menopause Society · 2008 · 294 citations
Medicine, Endocrinology, Gynecology +17
David Portman, Gloria Bachmann, James A. Simon · Menopause The Journal of The North American Menopause Society · 2013 · 245 citations
Marie Cerciat, Mikko Unkila, Luis Miguel García‐Segura et al. · Glia · 2009 · 160 citations